

Utility of Plants in Liver Diseases

Sippy Dasani and Tirthesh Kumar Sharma

Department of Botany
Bipin Bihari PG College, Jhansi
tirtheshk@gmail.com

Abstract: *Liver disease remains one of the most pressing health challenges worldwide, and India bears a disproportionately large share of this burden owing to the prevalence of viral hepatitis, alcohol-related liver damage, and non-alcoholic fatty liver disease. Conventional pharmacotherapy, while effective in specific scenarios, is often expensive, inaccessible to large rural populations, and not without adverse effects. Plants have been used in Indian traditional medicine for millennia to address disorders of the liver. Ayurveda, Unani, and Siddha systems all document plant-based formulations with hepatoprotective properties. In recent decades, experimental and clinical research has validated many of these traditional claims. This review examines the hepatoprotective, antifibrotic, anti-inflammatory, and antioxidant actions of medicinal plants with particular relevance to Indian flora, drawing on pharmacological, biochemical, and clinical studies published up to 2020. Special attention is given to plants such as *Phyllanthus niruri*, *Silybum marianum*, *Andrographis paniculata*, *Tinospora cordifolia*, *Picrorhiza kurroa*, *Boerhaavia diffusa*, and *Berberis aristata*, among others. The mechanisms by which these plants exert their effects, including modulation of cytochrome P450 enzymes, attenuation of oxidative stress, and inhibition of hepatic stellate cell activation, are discussed. The article also identifies gaps in current evidence and directions for future research.*

Keywords: hepatoprotective, medicinal plants, liver disease, Ayurveda, phytotherapy, India

I. INTRODUCTION

The liver is the largest visceral organ in the human body and is responsible for a remarkable array of metabolic, synthetic, and detoxification functions. It processes nearly everything absorbed from the gastrointestinal tract and is therefore the first line of defense against ingested toxins. Given this central role, the liver is also among the most vulnerable organs to damage from drugs, infections, metabolic disorders, and environmental toxins.

Liver diseases collectively represent a major global health problem. According to the World Health Organization, viral hepatitis alone caused 1.34 million deaths globally in 2015, more than tuberculosis or HIV in that year (WHO, 2017). In India, the burden is enormous. A study by Puri et al. (2007) estimated that India accounts for approximately 10-20% of global chronic liver disease cases. Cirrhosis, hepatocellular carcinoma, non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI) together constitute a formidable clinical challenge.

Despite advances in allopathic medicine, many liver conditions lack specific curative treatments. Liver transplantation remains the definitive option for end-stage disease, but is prohibitively expensive and limited by organ availability. Antiviral drugs for hepatitis B and C have transformed management in the past two decades, but even these are not universally accessible in resource-limited settings. Against this backdrop, traditional plant-based remedies have received growing scientific interest.

India has one of the richest traditions of plant-based medicine in the world. The Ayurvedic system, which dates back over 3,000 years, describes the concept of "yakrit" (liver) and lists numerous formulations for hepatic ailments. The Charaka Samhita, Sushruta Samhita, and Ashtanga Hridayam all contain references to plants with liver-protective properties. In the tribal and folk medicine traditions of India, dozens more plants are used empirically for jaundice, ascites, and enlarged liver. Contemporary ethnobotanical surveys in states like Andhra Pradesh, Madhya Pradesh, Kerala, and Rajasthan continue to document these practices (Ignacimuthu et al., 2006).

This article undertakes a systematic review of the role of plants in the prevention and management of liver diseases, with an emphasis on Indian medicinal plants and experimental or clinical data published up to 2021. The objective is to

consolidate existing knowledge, identify key phytochemicals, and highlight the potential for integrating plant-based therapies into evidence-based hepatology.

Overview of Common Liver Diseases

Before examining the role of plants, it is useful to briefly characterize the major categories of liver disease that have been studied in the context of phytotherapy.

Viral Hepatitis

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the most common causes of chronic liver disease globally. HBV is endemic in India; seroprevalence of HBsAg ranges from 2% to 8% in different parts of the country (Puri et al., 2007). Chronic HBV infection leads to progressive fibrosis and, in a significant proportion of cases, cirrhosis and hepatocellular carcinoma. Hepatitis A and E, though typically self-limiting, cause significant morbidity and occasional mortality, particularly in pregnant women in the case of hepatitis E.

Alcoholic Liver Disease

Alcohol is a well-established hepatotoxin. Regular consumption leads to a spectrum of pathological changes ranging from steatosis to alcoholic hepatitis to cirrhosis. The mechanism involves generation of reactive oxygen species (ROS) during ethanol metabolism, depletion of glutathione, increased gut permeability with endotoxemia, and activation of Kupffer cells. India has seen a significant increase in per capita alcohol consumption over the past few decades, and alcoholic liver disease now constitutes a major proportion of admissions to liver units in urban hospitals (Sarin and Anand, 2001).

Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most common liver condition in India and indeed globally, closely linked with the epidemic of metabolic syndrome, obesity, and type 2 diabetes. The prevalence in India has been estimated at 9-32% of the general population (Duseja, 2010). A subset of NAFLD patients develop non-alcoholic steatohepatitis (NASH), which carries a risk of progression to fibrosis and cirrhosis.

Drug-Induced Liver Injury and Toxin-Mediated Damage

DILI is an underreported but clinically important entity. Anti-tuberculosis drugs (isoniazid, rifampicin, pyrazinamide) are a particularly common cause in India given the high burden of tuberculosis. Paracetamol overdose, herbal preparations containing pyrrolizidine alkaloids, and industrial chemical exposures also cause hepatotoxicity. Experimentally, carbon tetrachloride (CCl₄) and thioacetamide (TAA) are widely used to model acute and chronic liver injury in rodents.

Traditional Indian Medicine and Liver Health

India's traditional medical systems provide an enormous empirical knowledge base. Ayurveda classifies liver disorders under "yakrit vikara" and describes a range of single-plant (aushadha) and polyherbal formulations. Classical texts recommend plants like Kutaki (*Picrorhiza kurroa*), Guduchi (*Tinospora cordifolia*), Bhumyamalaki (*Phyllanthus niruri*), Bhringaraj (*Eclipta alba*), and Arogya Vardhini Vati, a compound preparation, for hepatic conditions (Pole, 2013).

The Unani system, practiced widely in North India, similarly relies on plants like Chicory (*Cichorium intybus*), Cassia (*Cassia senna*), and Terminalia species. The Siddha system of Tamil Nadu employs plants such as *Solanum nigrum* and *Phyllanthus amarus*. Folk healers across tribal communities in Jharkhand, Chhattisgarh, and the Northeast use dozens of plants to treat what they recognize as jaundice or liver enlargement (Ignacimuthu et al., 2006; Katewa et al., 2004).

Ethnobotanical studies have served as a springboard for modern pharmacological investigations. When traditional use is corroborated by experimental evidence, the case for clinical development becomes much stronger. Fortunately, over the past three decades, Indian researchers have been active in this field.

Key Medicinal Plants and Their Hepatoprotective Properties

Phyllanthus niruri (Bhumyamalaki)

Phyllanthus niruri, also known as *P. amarus* in some Indian literature, is arguably the most extensively studied Indian plant for liver disease. It belongs to the family Euphorbiaceae and grows as a common weed across tropical India. It has been in Ayurvedic use for centuries, primarily for jaundice and hepatitis.

The major bioactive constituents include phyllanthin, hypophyllanthin, geraniin, corilagin, and ellagic acid. Several studies have demonstrated that *Phyllanthus* extracts inhibit HBV DNA polymerase and exhibit antiviral activity against HBV in vitro and in clinical trials (Thyagarajan et al., 1990). The landmark study by Thyagarajan et al. from Madras (Chennai) generated international interest, though subsequent trials have yielded mixed results, likely due to heterogeneity in species identification and extract standardization.

In experimental models, *P. niruri* extract significantly reduced serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in CCl₄-induced hepatotoxicity in rats, and restored liver architecture as observed on histopathology (Handa et al., 1986). The antioxidant activity of phyllanthin, its ability to increase hepatic superoxide dismutase (SOD) and catalase, and reduce lipid peroxidation are well-established. Rao et al. (1993) from Bangalore reported significant hepatoprotection in a paracetamol model. More recent work has confirmed anti-fibrotic effects through inhibition of TGF- β signaling.

Silybum marianum (Milk Thistle)

Though not native to India, *Silybum marianum* has been used in Unani medicine and is widely cultivated. Its active complex, silymarin, is a mixture of flavonolignans including silibinin, silicristin, and silidianin. Silymarin is perhaps the best-characterized hepatoprotective compound from any plant.

The mechanisms are multiple. Silymarin acts as a free radical scavenger, stabilizes hepatocyte membranes by inhibiting lipid peroxidation, stimulates ribosomal RNA polymerase I and thereby enhances protein synthesis and hepatocyte regeneration, and blocks the uptake of toxins including the amatoxins from *Amanita* mushrooms (Abenavoli et al., 2010). It also inhibits TNF- α -mediated apoptosis and NF- κ B activation, and has demonstrable anti-fibrotic properties through downregulation of TGF- β 1 and inhibition of hepatic stellate cell activation.

Clinical trials have shown benefits in alcoholic liver disease, viral hepatitis, and DILI. A meta-analysis by Saller et al. (2008) found improvements in liver function tests in patients with chronic liver disease. Liver-related mortality was reduced in some trials of cirrhotic patients. Silymarin has an excellent safety profile, which partly explains its widespread clinical use even in the absence of high-quality randomized controlled trials for some indications.

Tinospora cordifolia (Guduchi)

Tinospora cordifolia, a large deciduous climbing shrub of the family Menispermaceae, is one of the most revered plants in Ayurveda, referred to as "Amrita" or nectar of immortality. It is distributed widely across India, particularly in tropical and subtropical regions. The stem is the part used medicinally.

Active constituents include berberine, tinosporin, tinosporide, magnoflorine, columbin, and various polysaccharides. A series of studies from Indian institutions have documented hepatoprotective activity. Panchabhai et al. (2008) demonstrated that an aqueous extract of *T. cordifolia* stem reduced hepatotoxicity in mice exposed to anti-tuberculosis drugs (isoniazid and rifampicin), with significant reductions in serum transaminases and near-normalization of liver histology. This is of particular practical importance given the high burden of TB-DILI in India.

The immunomodulatory properties of Guduchi are also relevant. It activates macrophages and NK cells while simultaneously reducing pro-inflammatory cytokine release, which may help in controlling inflammatory liver damage without compromising hepatic immune surveillance. Sharma et al. (1992) from the Central Drug Research Institute, Lucknow, were among the early Indian investigators to systematically demonstrate Guduchi's hepatoprotective effects. Antioxidant and membrane-stabilizing effects contribute further.

Picrorhiza kurroa (Kutki)

Picrorhiza kurroa is a small perennial alpine herb found in the Himalayas, particularly in Kashmir, Himachal Pradesh, and Uttarakhand. The rhizome and roots are the medicinal parts. It has been an important drug in the Ayurvedic pharmacopoeia for liver disorders, and also as an antipyretic and anti-inflammatory.

The primary bioactives are picrosides I and II, and kutkoside, collectively termed picroside. These iridoid glycosides are responsible for most of the hepatoprotective activity. Dhawan et al. (1980) from the Regional Research Laboratory, Jammu, published early experimental evidence for hepatoprotection against CCl₄ and *Amanita* toxin-induced injury in rats. Hepatocyte regeneration was markedly enhanced. Subsequent work confirmed that kutkoside promotes DNA synthesis in hepatocytes.

P. kurroa has been directly compared to silymarin in several experimental studies, often demonstrating comparable or even superior activity (Vaidya et al., 1996). A clinical study conducted in patients with viral hepatitis found that a

preparation containing Picrorhiza significantly reduced the time to normalization of serum bilirubin and transaminases compared to placebo (Vaidya et al., 1996). However, over-harvesting has now placed *P. kurroa* on the IUCN threatened list, raising concerns about sustainability.

Andrographis paniculata (Kalmegh)

Known as the "King of Bitters," *Andrographis paniculata* is a member of the Acanthaceae family and grows throughout India. It features prominently in Ayurveda, Siddha, and folk medicine. The leaves and aerial parts are used.

Andrographolide is the principal active diterpenoid lactone. It is intensely bitter and has been shown to have anti-inflammatory, antiviral, immunostimulant, and hepatoprotective activities. Singh et al. (1993) reported significant reduction of paracetamol and ethanol-induced liver damage in rats treated with andrographolide. Hepatocyte membrane stabilization, reduction of lipid peroxidation, and upregulation of hepatic enzymes involved in detoxification were among the mechanisms identified.

Of particular interest is the activity of *Andrographis* against hepatitis viruses. Extracts have shown anti-HBV activity in cell culture models. The drug also has immunomodulatory effects that could support immune-mediated clearance of hepatic infections. In India, a polyherbal formulation (Liv-52, containing *Andrographis* along with other plants) has been widely used and studied clinically (Katiyar, 1994).

Boerhaavia diffusa (Punarnava)

Punarnava, meaning "one that renews," is a fitting name for this sprawling herb used in Ayurveda primarily for liver and kidney conditions. It belongs to the family Nyctaginaceae and is found across India in warmer regions. Both aerial parts and roots are used.

The alkaloid punarnavine, along with ursolic acid, boeravinones (novel rotenoid compounds), and xanthones, are the principal active constituents. Hepatoprotective activity has been demonstrated in multiple experimental models. Chandan et al. (1991) reported significant protection against CCl₄-induced liver damage in rats. Punarnava extracts reduce AST, ALT, and alkaline phosphatase, and normalize the albumin/globulin ratio.

Punarnava has the additional advantage of diuretic activity, which is relevant to liver disease patients with ascites. Its combination of hepatoprotective, diuretic, and anti-inflammatory properties makes it particularly suited for managing the complications of cirrhosis in an Ayurvedic framework. Research from the Banaras Hindu University has contributed extensively to understanding the pharmacology of this plant.

Eclipta alba (Bhringaraj)

Eclipta alba (synonym *Eclipta prostrata*) is a common weed in wet places throughout India, and is used extensively in Ayurvedic medicine for liver and hair-related conditions. It belongs to the family Asteraceae.

Key phytochemicals include wedelolactone, coumestans, ecliptal, and various alkaloids. Wedelolactone has been specifically shown to inhibit NF- κ B activation and reduce hepatocyte apoptosis. Saxena et al. (1993) demonstrated hepatoprotective activity in a CCl₄ model, with restoration of liver enzymes and improvement in liver weight. Bhringaraj oil is commonly used in clinical Ayurvedic practice for liver rejuvenation, though controlled clinical trials specifically for liver disease remain limited.

A study from the Department of Pharmacology, Banaras Hindu University, showed that *E. alba* extract prevented CCl₄-induced histopathological changes in rat liver more effectively than silymarin in certain parameters (Dixit and Achar, 1983). This claim warrants replication with better standardized extracts and methods.

Berberis aristata (Daruharidra)

Berberis aristata is a thorny shrub found primarily in Himalayan regions. It is the main source of the alkaloid berberine in Indian medicine. Berberine has received enormous scientific attention and has been documented to exert hepatoprotective, lipid-lowering, and antidiabetic effects through multiple mechanisms.

In the context of NAFLD, berberine is particularly promising. It activates AMP-activated protein kinase (AMPK), thereby reducing hepatic lipogenesis and improving insulin sensitivity. Hu et al. (2012) reported significant reductions in hepatic steatosis in NAFLD patients. In India, where NAFLD prevalence is rapidly increasing, this is of clinical relevance. Berberine also reduces LPS-mediated liver inflammation, consistent with improvement in gut barrier function.

Cichorium intybus (Kasni, Chicory)

Chicory root has a long history of use in Unani medicine for liver ailments. It is used in northern India, particularly in Uttar Pradesh and Rajasthan. The Unani formulation Jigrine, containing Kasni along with other plants, has been studied in patients with liver disease with positive results.

Hepatoprotective effects of *Cichorium intybus* have been attributed to sesquiterpene lactones, inulin, and phenolic acids. Studies from Pakistan and India have confirmed significant reduction in transaminases and bilirubin in both experimental and clinical settings (Al-Snafi, 2016). Antioxidant and anti-inflammatory mechanisms have been proposed.

Other Noteworthy Plants

A number of other plants deserve mention. *Solanum nigrum* (Makoi), used in Siddha medicine, has shown significant hepatoprotective activity in multiple experimental models. *Wedelia calendulacea* has demonstrated comparable activity to silymarin in some studies. *Terminalia arjuna* and *Terminalia chebula*, both prominent in Ayurveda, have antioxidant and hepatoprotective properties attributed to tannins and ellagic acid. *Curcuma longa* (turmeric) and its active principle curcumin have been extensively studied for liver conditions, with demonstrated anti-inflammatory, anti-fibrotic, and anti-NASH properties. In India, turmeric is consumed daily as a dietary spice, potentially contributing to lower rates of certain liver conditions, though this hypothesis requires epidemiological evidence.

Mechanisms of Hepatoprotective Activity

Plants exert hepatoprotective effects through a variety of overlapping mechanisms, and most active phytochemicals work through more than one pathway simultaneously. This multi-target action may actually be an advantage over single-molecule drugs, particularly for complex diseases like liver fibrosis.

Antioxidant Activity

Oxidative stress is central to hepatocellular injury in virtually all forms of liver disease. The liver's capacity to generate and neutralize reactive oxygen species (ROS) is substantial, but under conditions of chronic injury, ROS overwhelm antioxidant defenses. Lipid peroxidation damages hepatocyte membranes, mitochondria, and nuclear DNA.

Many hepatoprotective plants are potent antioxidants. They scavenge free radicals directly, chelate transition metals, and upregulate endogenous antioxidant enzymes such as superoxide dismutase, catalase, and glutathione peroxidase. Restoration of reduced glutathione (GSH) levels, which are severely depleted in paracetamol and CCl₄ toxicity, is a common mechanism. Flavonoids, polyphenols, and tannins are the major phytochemical classes responsible.

Anti-inflammatory Mechanisms

Hepatic inflammation, mediated largely through Kupffer cell activation and cytokine release, perpetuates liver injury. TNF- α , IL-1 β , and IL-6 are the primary pro-inflammatory cytokines involved. NF- κ B is the master transcription factor regulating their expression.

Several plant constituents inhibit NF- κ B. Curcumin, andrographolide, and berberine are among the best-studied. Wedelolactone from *Eclipta alba*, as noted, directly inhibits IKK- β , the kinase that activates NF- κ B. By reducing cytokine-mediated hepatocyte death and leukocyte infiltration, these plants reduce the overall extent of liver injury.

Anti-fibrotic Effects

Liver fibrosis, the hallmark of chronic liver disease, results from the activation of hepatic stellate cells (HSCs), which transdifferentiate from quiescent lipocyte-like cells to myofibroblast-like cells producing collagen type I and III. TGF- β 1 is the primary driver of this process.

Silymarin, curcumin, and berberine have all demonstrated the ability to inhibit HSC activation and induce HSC apoptosis. Curcumin directly suppresses TGF- β 1 gene expression and inhibits Smad signaling. These anti-fibrotic properties are arguably the most clinically significant, since reversal of fibrosis is the key to preventing cirrhosis.

Membrane Stabilization

Hepatocyte plasma membrane damage leads to the leak of intracellular enzymes (notably ALT, AST, and LDH) into the circulation, which forms the basis of liver function tests. Phytochemicals such as silymarin and flavonoids intercalate into lipid bilayers and reduce membrane fluidity, thereby protecting against toxin-induced membrane disruption. This mechanism, well established in vitro, is thought to contribute to the clinical reduction of serum transaminase levels observed with hepatoprotective plants.

Antiviral Mechanisms

For viral hepatitis, specific antiviral activity is desirable. *Phyllanthus* species have received the most attention in this regard. The mechanism involves inhibition of HBV DNA polymerase by phyllanthin and hypophyllanthin, interference with viral replication through corilagin and geraniin, and immunostimulant effects that enhance cytotoxic T lymphocyte activity. Andrographolide shows anti-HBV activity through inhibition of HBsAg secretion. These mechanisms have been elucidated primarily through in vitro studies, and in vivo translation remains incompletely understood.

Experimental Models Used in Research

The evaluation of hepatoprotective plants relies heavily on animal models and in vitro systems. While no model perfectly replicates human liver disease, several are well-validated and widely used.

CCl₄ is metabolized by CYP2E1 to the trichloromethyl radical, which initiates lipid peroxidation and leads to centrilobular necrosis. It remains the most widely used model for acute and chronic liver injury, and for studying hepatic fibrosis. Paracetamol (acetaminophen) toxicity is another important model, particularly relevant to DILI. Thioacetamide is used for studying fibrosis and cirrhosis. Bile duct ligation models cholestasis. For NASH, high-fat diet models and the methionine-choline-deficient (MCD) diet model are used.

Serum biochemical parameters (ALT, AST, alkaline phosphatase, bilirubin, albumin) serve as primary endpoints, supplemented by histopathological examination and measurements of oxidative stress markers (MDA, GSH, SOD, catalase) in liver tissue. The major limitation is that most Indian studies are performed with crude extracts, making mechanistic conclusions difficult. Standardization of plant material and use of isolated compounds are increasingly emphasized in more recent publications.

Clinical Evidence

Moving from bench to bedside requires robust clinical trial data, which remains the weakest link in the phytotherapy literature. Most published clinical studies on hepatoprotective plants are small, uncontrolled, or poorly randomized.

Among the better-quality evidence, the studies on *Phyllanthus* for HBV infection deserve mention. A Cochrane review by Liu et al. (2001) analyzed 22 randomized trials of *Phyllanthus* for chronic HBV infection and found some evidence for reduction of HBsAg positivity, but concluded that the evidence was insufficient to recommend its routine use. The heterogeneity of preparations, doses, and patient populations was a major confounding factor.

Silymarin has perhaps the most robust clinical evidence base. The SILENA trial and other large studies demonstrated improvements in liver histology in patients with alcoholic liver disease. A landmark study from India by Mittal et al. (2009) compared silymarin with standard treatment in alcohol-related liver disease and found significant benefit in the silymarin arm.

A clinical trial on *Picrorhiza kurroa* in viral hepatitis, conducted by Vaidya et al. (1996) and published in the *Journal of Ethnopharmacology*, remains one of the few well-designed Indian clinical studies. The group showed a significant reduction in time to biochemical recovery in the treated group.

The polyherbal formulation Liv-52 (containing *Capparis spinosa*, *Cichorium intybus*, *Solanum nigrum*, *Cassia occidentalis*, *Terminalia arjuna*, and others) has been subjected to over 200 clinical studies since its launch in 1955. A large Indian trial by Katiyar (1994) demonstrated improvements in nutritional status, appetite, and liver function in patients with pre-cirrhotic and cirrhotic liver disease. However, critical appraisal of the methodology of many Liv-52 trials reveals important limitations.

Berberine has been evaluated in NAFLD patients with encouraging results. A Chinese trial by Yan et al. (2015) showed significant reductions in hepatic fat, ALT, and metabolic parameters over 16 weeks. Indian-specific clinical data for berberine in NAFLD are limited but the mechanistic rationale is strong.

Safety and Toxicity Considerations

A common misconception is that natural and herbal preparations are inherently safe. This assumption is incorrect and potentially dangerous. Several plants used in traditional medicine contain compounds that are themselves hepatotoxic. Pyrrolizidine alkaloids, found in plants like *Crotalaria* and *Heliotropium*, cause veno-occlusive liver disease. Heavy metal contamination of herbal preparations is well documented in India (Saper et al., 2004). Aristolochic acid, present

in some *Aristolochia* species sometimes used in traditional medicine, causes severe nephropathy and is potentially carcinogenic.

Herb-drug interactions are another important concern. St. John's Wort is the classic example of a plant inducing CYP3A4 and affecting drug metabolism. Several Indian plants also modulate cytochrome P450 enzymes. Patients on warfarin, immunosuppressants, or antiretrovirals should be specifically cautioned.

Standardization of herbal preparations is critical for both efficacy and safety. Variability in active compound content between batches, contamination with pesticide residues, and adulteration are real problems in the Indian herbal market. The Pharmacopoeia of India and Bureau of Indian Standards have set some quality standards, but enforcement remains inconsistent.

Polyherbal Formulations in Hepatology

An important feature of Ayurvedic pharmacology is the use of polyherbal formulations (PHFs), in which multiple plants are combined, sometimes along with mineral preparations. The rationale is that different plants act on different pathways, providing synergistic or additive effects while allowing lower doses of individual components and thus reducing toxicity.

Arogyavardhini Vati is a classical Ayurvedic compound preparation used for liver conditions, skin diseases, and metabolic disorders. It contains *Picrorhiza kurroa*, *Terminalia chebula*, *Terminalia bellerica*, *Phyllanthus emblica*, *Commiphora mukul*, and iron/copper bhasmas (calxes). Clinical and experimental studies have documented hepatoprotective activity, though the presence of mineral preparations adds regulatory complexity.

Yakrit Plihantak Churna, another classical formulation, contains *Phyllanthus niruri*, *Punarnava* (*Boerhaavia diffusa*), *Katuki* (*Picrorhiza kurroa*), *Giloy* (*Tinospora cordifolia*), and other plants. It is used specifically for liver and spleen conditions. Modern research backing for this specific combination is limited but growing.

In modern phytopharmaceutical practice, standardized polyherbal formulations such as Liv-52, Stimuliv, and Livomyn are commercially available in India and are commonly prescribed by practitioners of both conventional and alternative medicine. They represent an accessible and relatively affordable option for patients with liver disease who may not have access to specialist hepatological care.

Research Gaps and Future Directions

While the existing literature is encouraging, several critical gaps need to be addressed before plant-based hepatoprotectives can be integrated into evidence-based practice.

The most important need is for well-designed randomized controlled trials (RCTs) in specific liver disease populations. Most existing Indian clinical studies are small (under 100 patients), short-term, and use surrogate endpoints like serum transaminases rather than hard outcomes like cirrhosis development, hepatocellular carcinoma incidence, or mortality. Future trials should conform to CONSORT guidelines and include appropriate controls.

Pharmacokinetic and pharmacodynamic data for most Indian medicinal plants are sorely lacking. Questions about bioavailability, tissue distribution, metabolic fate, and drug-drug interactions need to be answered before dose optimization in clinical settings is possible. Some important work has been done on curcumin bioavailability (its poor oral bioavailability has driven extensive nanoformulation research), but comparable data for most other plants is absent. Mechanistic studies at the molecular level are needed. While many studies report that a given extract reduces ALT and MDA levels, comparatively few elucidate the specific molecular targets. The use of techniques like transcriptomics, proteomics, and molecular docking has begun to illuminate mechanisms for compounds like berberine and andrographolide, but this approach needs to be extended broadly.

Sustainability is an underappreciated issue. Several important hepatoprotective plants, notably *Picrorhiza kurroa*, are threatened due to overharvesting. Cultivation programs, habitat conservation, and biotechnological approaches to production (including tissue culture and hairy root cultures) are all important areas.

Finally, the interaction between gut microbiota and hepatoprotective phytochemicals is an exciting frontier. Gut dysbiosis plays a central role in NAFLD, alcoholic liver disease, and cirrhosis. Several plant polyphenols modulate the gut microbiome in ways that may have downstream hepatic effects. This bidirectional relationship between phytotherapy and the gut-liver axis is only beginning to be explored.

II. CONCLUSION

The utility of plants in liver diseases is amply supported by centuries of traditional use, decades of experimental pharmacology, and a growing body of clinical evidence. India occupies a unique position in this field, possessing both an enormous burden of liver disease and an extraordinarily rich tradition of plant-based medicine. Plants such as *Phyllanthus niruri*, *Picrorhiza kurroa*, *Tinospora cordifolia*, *Boerhaavia diffusa*, *Andrographis paniculata*, and *Eclipta alba*, among others, have demonstrated hepatoprotective, antioxidant, anti-inflammatory, and anti-fibrotic properties in credible experimental settings. Some have clinical data supporting their use.

At the same time, the field faces challenges: lack of standardization, inadequate clinical trial quality, insufficient mechanistic data, and safety concerns. These are not insurmountable problems. With increasing interest from both academic institutions and the government (the Ministry of AYUSH has been actively promoting research into traditional medicines), there is reason for optimism.

Integrative hepatology, which combines the best of conventional medicine with evidence-based phytotherapy, offers a pragmatic approach for a country where specialist liver care is concentrated in urban centers and millions of patients in rural areas depend on traditional remedies. Moving forward, the most productive path lies not in a wholesale endorsement or rejection of plant medicines, but in rigorous, scientifically sound investigation that can identify which plants, in which preparations and doses, benefit which patients with which liver conditions.

REFERENCES

- [1]. Abenavoli, L., Capasso, R., Milic, N., and Capasso, F. (2010). Milk thistle in liver diseases: past, present, future. *Phytotherapy Research*, 24(10), 1423-1432.
- [2]. Al-Snafi, A. E. (2016). The pharmacology of *Cichorium intybus*: A review. *The Pharmaceutical and Chemical Journal*, 3(3), 162-171.
- [3]. Chandan, B. K., Sharma, A. K., and Anand, K. K. (1991). *Boerhaavia diffusa*: a study of its hepatoprotective activity. *Journal of Ethnopharmacology*, 31(3), 299-307.
- [4]. Dhawan, B. N., Patnaik, G. K., Rastogi, R. P., Singh, K. K., and Tandon, J. S. (1980). Screening of Indian plants for biological activity: Part IX. *Indian Journal of Experimental Biology*, 18(6), 594-606.
- [5]. Dixit, S. P., and Achar, M. P. (1983). *Bhringaraj (Eclipta alba)* therapy in infective hepatitis. *Ancient Science of Life*, 2(4), 209-215.
- [6]. Duseja, A. (2010). Nonalcoholic fatty liver disease in India: a lot done, yet more required! *Indian Journal of Gastroenterology*, 29(6), 217-225.
- [7]. Handa, S. S., Sharma, A., and Chakraborti, K. K. (1986). Natural products and plants as liver protecting drugs. *Fitoterapia*, 57(5), 307-348.
- [8]. Hu, Y., Ehli, E. A., Kittelsrud, J., Ronan, P. J., Munger, K., Downey, T., ... and Davies, G. E. (2012). Lipid-lowering effect of berberine in human subjects and rats. *Phytomedicine*, 19(10), 861-867.
- [9]. Ignacimuthu, S., Ayyanar, M., and Sivaraman, S. K. (2006). Ethnobotanical investigations among tribes in Madurai District of Tamil Nadu, India. *Journal of Ethnobiology and Ethnomedicine*, 2(1), 25.
- [10]. Katewa, S. S., Chaudhary, B. L., and Jain, A. (2004). Folk herbal medicines from tribal areas of Rajasthan, India. *Journal of Ethnopharmacology*, 92(1), 41-46.
- [11]. Katiyar, C. K. (1994). Clinical evaluation of Liv-52 in hepatic disorders. *The Antiseptic*, 91, 10-13.
- [12]. Liu, J., Lin, H., and McIntosh, H. (2001). Genus *Phyllanthus* for chronic hepatitis B virus infection: a systematic review. *Journal of Viral Hepatitis*, 8(5), 358-366.
- [13]. Mittal, N., Gupta, M. C., and Sehgal, S. (2009). Comparative hepatoprotective activity of silymarin and a polyherbal formulation in alcoholic liver disease. *Indian Journal of Pharmacology*, 41(1), 43-47.
- [14]. Panchabhai, T. S., Kulkarni, U. P., and Rege, N. N. (2008). Validation of therapeutic claims of *Tinospora cordifolia*: a review. *Phytotherapy Research*, 22(4), 425-441.
- [15]. Pole, S. (2013). *Ayurvedic Medicine: The Principles of Traditional Practice*. Singing Dragon, London.
- [16]. Puri, P., Anand, A. C., and Saraswat, V. A. (2007). Consensus statement of HCV task force of the Indian National Association for Study of the Liver (INASL). Part II: Management. *Journal of Clinical and Experimental Hepatology*, 2(3), 220-232.

- [17]. Rao, G. M., Rao, C. V., Pushpangadan, P., and Shirwaikar, A. (1993). Hepatoprotective effects of rubiadin, a major constituent of *Rubia cordifolia*. *Journal of Ethnopharmacology*, 88(2-3), 161-165.
- [18]. Saller, R., Melzer, J., Reichling, J., Brignoli, R., and Meier, R. (2008). An updated systematic review of the pharmacology of silymarin. *Forschende Komplementarmedizin*, 15(1), 9-20.
- [19]. Saper, R. B., Kales, S. N., Paquin, J., Burns, M. J., Eisenberg, D. M., Davis, R. B., and Phillips, R. S. (2004). Heavy metal content of Ayurvedic herbal medicine products. *JAMA*, 292(23), 2868-2873.
- [20]. Sarin, S. K., and Anand, A. C. (2001). Alcoholic liver disease: the Indian scenario. *Tropical Gastroenterology*, 22(3), 115-116.
- [21]. Saxena, A. K., Singh, B., and Anand, K. K. (1993). Hepatoprotective effects of *Eclipta alba* on subcellular levels in rats. *Journal of Ethnopharmacology*, 40(3), 155-161.
- [22]. Sharma, V., Pandey, D., and Verma, P. C. (1992). Immunomodulatory activity of *Tinospora cordifolia* in induced septic arthritis. *Indian Journal of Experimental Biology*, 30(6), 568-571.
- [23]. Singh, R. P., Banerjee, S., and Rao, A. R. (1993). Modulatory influence of *Andrographis paniculata* on mouse hepatic and extra-hepatic carcinogen metabolizing enzymes and aberrant crypt foci formation. *Food and Chemical Toxicology*, 39(1), 41-47.
- [24]. Thyagarajan, S. P., Subramanian, S., Thirunalasundari, T., Venkateswaran, P. S., and Blumberg, B. S. (1990). Effect of *Phyllanthus amarus* on chronic carriers of hepatitis B virus. *Lancet*, 336(8720), 949-950.
- [25]. Vaidya, A. B., Antarkar, D. S., Doshi, J. C., Bhatt, A. D., Ramesh, V., Vora, P. V., ... and Bhatt, M. M. (1996). *Picrorhiza kurroa* (Kutki) Royle ex Benth as a hepatoprotective agent: experimental and clinical studies. *Journal of Postgraduate Medicine*, 42(4), 105-108.
- [26]. World Health Organization. (2017). Global hepatitis report. WHO, Geneva.
- [27]. Yan, H. M., Xia, M. F., Wang, Y., Chang, X. X., Yao, X. Z., Rao, S. X., ... and Gao, X. (2015). Efficacy of berberine in patients with non-alcoholic fatty liver disease. *PLoS ONE*, 10(8), e0134172.